Anybody used Adequan? - Joint Medication

[Ronin_]

Ive heard some good things about this stuff, namely that it is great at rehabing and even fixing worn out joints. Has anyone used this? It is indicated for joint problems in dogs and horses, and is an IM injection

Here's some info:

First, Adequan has important antiinflammatory effects, so it is able to provide relief from the symptoms of joint damage: heat, swelling, pain and lameness. And Adequan can be found in synovial fluid at full therapeutic levels within only two hours of an intramuscular injection. Also, Adequan is a product with potent ability to block the action of the destructive enzymes that threaten to perpetuate the joint inflammation, attack the cartilage and break down synovial fluid.

Second, Adequan also stimulates the synovial membrane to manufacture new, viscous synovial fluid to replace the thin fluid that was produced when the joint became injured. By improving this fluid, Adequan helps the joint regain its ability to lubricate and guard itself against further inflammation, and helps reestablish nutrition to the cartilage.

And, Adequan attaches itself to damaged cartilage where it has a positive effect on cartilage metabolism. This should favor the cartilage repair process.

Adequan is the only joint treatment proven to reduce the inflammation and pain of degenerative joint disease, but also to help stop the degenerative process while stimulating the production of new joint fluid and new cartilage components. You are no longer just treating symptoms: you're doing something to help stop the degenerative process

[atlas]

who has that?

[Ronin_]

You have to buy it from vet supplies bro - it requires a prescription but I know of a few places where they waive it if none provided

[STNCLD]

Ronin,
Have you tried this stuff yet?
I would like somemore info on it if you have found anything. I think this would help my father who needs a new hip, and me for shoulders. Could you post any extra info if you have it. I am going to start trying to find some more info as well.
Thanks bro
Stncld

[Ronin_]

yeah ill research tomoro bro, my joints are shot to shit so it would be a god send

[Ronin_]

here's some more info:

ADEQUAN ® CANINE Brand of Polysulfated Glycosaminoglycan Solution 100 mg/mL in a 5 mL preserved Multiple dose vial for intramuscular use in dogs



Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



Description: The active ingredient in Adequan ® Canine is polysulfated glycosaminoglycan (PSGAG). Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan prepared by extracting glycosaminoglycans (GAGs) from bovine tracheal cartilage. GAGs are polysaccharides composed of repeating disaccharide units. The GAG present in PSGAG is principally chondroitin sulfate containing 3 to 4 sulfate esters per disaccharide unit. The molecular weight for PSGAG used in the manufacture of Adequan ® is 3,000 to 15,000 daltons. Each mL of Adequan ® Canine contains 100 mg of PSGAG, 0.9% v/v benzyl alcohol as a preservative, and water for injection q.s. to 1 mL. Sodium hydroxide and/or hydrochloric acid added when necessary to adjust pH.



Pharmacology: The specific mechanism of action of Adequan ® in canine joints is not known. PSGAG is characterized as a "disease modifying osteoarthritis drug." Experiments conducted in vitro have shown PSGAG to inhibit certain catabolic enzymes which have increased activity in inflamed joints, and to enhance the activity of some anabolic enzymes. For example, PSGAG has been shown to significantly inhibit serine proteinases. Serine proteinases have been demonstrated to play a role in the Interleukin-1 mediated degradation of cartilage proteoglycans and collagen. PSGAG is reported to be an inhibitor of Prostaglandin E2 (PGE2) synthesis. PGE2 has been shown to increase the loss of proteoglycan from cartilage. PSGAG has been reported to inhibit some catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin B1, and hyaluronidases, which degrade collagen, proteoglycans, and hyaluronic acid in degenerative joint disease. Anabolic effects studied include ability to stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid in various cells and tissues in vitro. Cultured human and rabbit chondrocytes have shown increased synthesis of proteoglycan and hyaluronic acid in the presence of PSGAG. PSGAGs have shown a specific potentiating effect on hyaluronic acid synthesis by synovial membrane cells in vitro.



Absorption, distribution, metabolism, and excretion of PSGAG following intramuscular injection have been studied in several species, including rats, rabbits, humans, and dogs.



Studies in rabbits showed maximum blood concentrations of PSGAG following IM injection were reached between 20 to 40 minutes following injection, and that the drug was distributed to all tissues studied, including articular cartilage, synovial fluid, adrenals, thyroid, peritoneal fluid, lungs, eyes, spinal cord, kidneys, brain, liver, spleen, bone marrow, skin, and heart.



Following intramuscular injection of PSGAG in humans, the drug was found to be bound to serum proteins. PSGAG binds to both albumin and chi- and beta-globulins and the extent of the binding is suggested to be 30 to 40%. Therefore, the drug may be present in both bound and free form in the bloodstream. Because of its relatively low molecular weight, the synovial membrane is not a significant barrier to distribution of PSGAG from the bloodstream to the synovial fluid. Distribution from the synovial fluid to the cartilage takes place by diffusion. In the articular cartilage the drug is deposited into the cartilage matrix.



Serum and synovial fluid distribution curves of PSGAG have been studied in dogs and appear similar to those found in humans and rabbits. In rabbits, metabolism of PSGAG is reported to take place in the liver, spleen, and bone marrow. Metabolism may also occur in the kidneys. PSGAG administered intramuscularly and not protein bound or bound to other tissues is excreted primarily via the kidneys, with a small proportion excreted in the feces.



Toxicity: In a subacute toxicity study, 32 adult beagle dogs (4 males and 4 females per treatment group) received either 0.9% saline solution or PSGAG at a dose of 5 mg, 15 mg, or 50 mg per kg of body weight (approximately 2.3, 6.8, or 22.7 mg/lb), via intramuscular injection twice weekly for 13 weeks. PSGAG doses represent approximately 1X, 3X, and 10X the recommended dosage of 2 mg/lb, and more than 3 times the recommended 4-week duration of treatment. Necropsies were performed 24 hours after the final treatment. During week 12, one dog in the 50 mg/kg dosage group developed a large hematoma at the injection site which necessitated euthanasia. No other mortalities occurred during the treatment period. Statistically significant changes in the 50 mg/kg group included increased prothrombin time, reduced platelet count, an increase in ALT and cholesterol, and increased liver and kidney weights. Increased cholesterol and kidney weights were also noted in the 15 mg/kg group. Microscopic lesions were noted in the liver (Kupffer cells containing eosinophilic foamy cytoplasm), kidneys (swollen, foamy cells in the proximal convoluted tubules), and lymph nodes (macrophages with eosinophilic foamy cytoplasm) in the 15 mg/kg and 50 mg/kg groups. Intramuscular inflammation, hemorrhage, and degeneration were seen in all 3 PSGAG treated groups; the incidence and severity appeared dose related.


Efficacy: Efficacy of Adequan ® Canine was demonstrated in two studies. A laboratory study using radiolabeled PSGAG established distribution of PSGAG into canine serum and synovial fluid following a single intramuscular injection of 2 mg/lb. A clinical field trial was conducted in dogs diagnosed with radiographically-confirmed traumatic and/or degenerative joint disease of 1 or 2 joints. Joints evaluated included hips, stifles, shoulders, hocks and elbows. Fifty-one dogs were randomly assigned to receive either Adequan ® Canine at 2 mg/lb of body weight or 0.9% saline. Both treatments were administered by intramuscular injection twice weekly for 4 weeks (8 injections total). Investigators administering treatment and evaluating the dogs were unaware of the treatment assignment. A total of 71 limbs in 51 dogs were evaluated. Of these, 35 limbs in 24 dogs were in the Adequan ® Canine treated group. Each lame limb was scored for lameness at a walk, lameness at a trot, pain, range of motion, and functional disability. The scores for the individual parameters were combined to determine a total orthopedic score. At the end of the treatment period, dogs treated with Adequan ® Canine showed a statistically significant improvement in range of motion and total orthopedic score over placebo treated control dogs.


Indications and Usage: Adequan ® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.


Contraindications: Do not use in dogs showing hypersensitivity to PSGAG. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.


Reproductive Safety: Studies to establish the safety of Adequan ® Canine in breeding, pregnant, or lactating dogs have not been conducted.


Precaution: Use with caution in dogs with renal or hepatic impairment.


Adverse Reactions: In the clinical efficacy trial, 24 dogs were treated with Adequan ® Canine twice weekly for 4 weeks. Possible adverse reactions were reported after 2.1% of the injections. These included transient pain at the injection site (1 incident), transient diarrhea (1 incident each in 2 dogs), and abnormal bleeding (1 incident). These effects were mild and self-limiting and did not require interruption of therapy. To report suspected adverse reactions or for a copy of the Material Safety Data Sheet for this product, contact Luitpold Pharmaceuticals, Inc. at 1-800-458-0163.

[einstein1905]

Originally Posted by Ronin_

here's some more info:

ADEQUAN ® CANINE Brand of Polysulfated Glycosaminoglycan Solution 100 mg/mL in a 5 mL preserved Multiple dose vial for intramuscular use in dogs



Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



Description: The active ingredient in Adequan ® Canine is polysulfated glycosaminoglycan (PSGAG). Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan prepared by extracting glycosaminoglycans (GAGs) from bovine tracheal cartilage. GAGs are polysaccharides composed of repeating disaccharide units. The GAG present in PSGAG is principally chondroitin sulfate containing 3 to 4 sulfate esters per disaccharide unit. The molecular weight for PSGAG used in the manufacture of Adequan ® is 3,000 to 15,000 daltons. Each mL of Adequan ® Canine contains 100 mg of PSGAG, 0.9% v/v benzyl alcohol as a preservative, and water for injection q.s. to 1 mL. Sodium hydroxide and/or hydrochloric acid added when necessary to adjust pH.



Pharmacology: The specific mechanism of action of Adequan ® in canine joints is not known. PSGAG is characterized as a "disease modifying osteoarthritis drug." Experiments conducted in vitro have shown PSGAG to inhibit certain catabolic enzymes which have increased activity in inflamed joints, and to enhance the activity of some anabolic enzymes. For example, PSGAG has been shown to significantly inhibit serine proteinases. Serine proteinases have been demonstrated to play a role in the Interleukin-1 mediated degradation of cartilage proteoglycans and collagen. PSGAG is reported to be an inhibitor of Prostaglandin E2 (PGE2) synthesis. PGE2 has been shown to increase the loss of proteoglycan from cartilage. PSGAG has been reported to inhibit some catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin B1, and hyaluronidases, which degrade collagen, proteoglycans, and hyaluronic acid in degenerative joint disease. Anabolic effects studied include ability to stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid in various cells and tissues in vitro. Cultured human and rabbit chondrocytes have shown increased synthesis of proteoglycan and hyaluronic acid in the presence of PSGAG. PSGAGs have shown a specific potentiating effect on hyaluronic acid synthesis by synovial membrane cells in vitro.



Absorption, distribution, metabolism, and excretion of PSGAG following intramuscular injection have been studied in several species, including rats, rabbits, humans, and dogs.



Studies in rabbits showed maximum blood concentrations of PSGAG following IM injection were reached between 20 to 40 minutes following injection, and that the drug was distributed to all tissues studied, including articular cartilage, synovial fluid, adrenals, thyroid, peritoneal fluid, lungs, eyes, spinal cord, kidneys, brain, liver, spleen, bone marrow, skin, and heart.



Following intramuscular injection of PSGAG in humans, the drug was found to be bound to serum proteins. PSGAG binds to both albumin and chi- and beta-globulins and the extent of the binding is suggested to be 30 to 40%. Therefore, the drug may be present in both bound and free form in the bloodstream. Because of its relatively low molecular weight, the synovial membrane is not a significant barrier to distribution of PSGAG from the bloodstream to the synovial fluid. Distribution from the synovial fluid to the cartilage takes place by diffusion. In the articular cartilage the drug is deposited into the cartilage matrix.



Serum and synovial fluid distribution curves of PSGAG have been studied in dogs and appear similar to those found in humans and rabbits. In rabbits, metabolism of PSGAG is reported to take place in the liver, spleen, and bone marrow. Metabolism may also occur in the kidneys. PSGAG administered intramuscularly and not protein bound or bound to other tissues is excreted primarily via the kidneys, with a small proportion excreted in the feces.



Toxicity: In a subacute toxicity study, 32 adult beagle dogs (4 males and 4 females per treatment group) received either 0.9% saline solution or PSGAG at a dose of 5 mg, 15 mg, or 50 mg per kg of body weight (approximately 2.3, 6.8, or 22.7 mg/lb), via intramuscular injection twice weekly for 13 weeks. PSGAG doses represent approximately 1X, 3X, and 10X the recommended dosage of 2 mg/lb, and more than 3 times the recommended 4-week duration of treatment. Necropsies were performed 24 hours after the final treatment. During week 12, one dog in the 50 mg/kg dosage group developed a large hematoma at the injection site which necessitated euthanasia. No other mortalities occurred during the treatment period. Statistically significant changes in the 50 mg/kg group included increased prothrombin time, reduced platelet count, an increase in ALT and cholesterol, and increased liver and kidney weights. Increased cholesterol and kidney weights were also noted in the 15 mg/kg group. Microscopic lesions were noted in the liver (Kupffer cells containing eosinophilic foamy cytoplasm), kidneys (swollen, foamy cells in the proximal convoluted tubules), and lymph nodes (macrophages with eosinophilic foamy cytoplasm) in the 15 mg/kg and 50 mg/kg groups. Intramuscular inflammation, hemorrhage, and degeneration were seen in all 3 PSGAG treated groups; the incidence and severity appeared dose related.


Efficacy: Efficacy of Adequan ® Canine was demonstrated in two studies. A laboratory study using radiolabeled PSGAG established distribution of PSGAG into canine serum and synovial fluid following a single intramuscular injection of 2 mg/lb. A clinical field trial was conducted in dogs diagnosed with radiographically-confirmed traumatic and/or degenerative joint disease of 1 or 2 joints. Joints evaluated included hips, stifles, shoulders, hocks and elbows. Fifty-one dogs were randomly assigned to receive either Adequan ® Canine at 2 mg/lb of body weight or 0.9% saline. Both treatments were administered by intramuscular injection twice weekly for 4 weeks (8 injections total). Investigators administering treatment and evaluating the dogs were unaware of the treatment assignment. A total of 71 limbs in 51 dogs were evaluated. Of these, 35 limbs in 24 dogs were in the Adequan ® Canine treated group. Each lame limb was scored for lameness at a walk, lameness at a trot, pain, range of motion, and functional disability. The scores for the individual parameters were combined to determine a total orthopedic score. At the end of the treatment period, dogs treated with Adequan ® Canine showed a statistically significant improvement in range of motion and total orthopedic score over placebo treated control dogs.


Indications and Usage: Adequan ® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.


Contraindications: Do not use in dogs showing hypersensitivity to PSGAG. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.


Reproductive Safety: Studies to establish the safety of Adequan ® Canine in breeding, pregnant, or lactating dogs have not been conducted.


Precaution: Use with caution in dogs with renal or hepatic impairment.


Adverse Reactions: In the clinical efficacy trial, 24 dogs were treated with Adequan ® Canine twice weekly for 4 weeks. Possible adverse reactions were reported after 2.1% of the injections. These included transient pain at the injection site (1 incident), transient diarrhea (1 incident each in 2 dogs), and abnormal bleeding (1 incident). These effects were mild and self-limiting and did not require interruption of therapy. To report suspected adverse reactions or for a copy of the Material Safety Data Sheet for this product, contact Luitpold Pharmaceuticals, Inc. at 1-800-458-0163.

This was going to be a PM, but your box is full.

I'm looking at Adequan too. I'd by the equine just because it's cheaper (more mg/mL at a cheaper price). Looks like a few sites don't ask about scripts. For humans, it may be better to shoot IA instead of IM..you'll use much less, and it will alleviate a lot of the binding by albumin in the bloodstream. For me anyway, I have one knee that is bad, and that's what I'd target....I may also go IM too to see if I get an improved "feeling" at other joints too.
There is an MD that has patented IA GH shots. It looks like 3-5IU shots into the joint capsule. I may do this once a week too.
If you beat me to using the Adequan or get any feedback from those that have used it, let me know. I'll do the same.
Take care.

[Ronin_]

Hi there bro - I have spoke to a few people now who say it is very good, and also a drug called Sodium Hydrlonate which is meant to be excellent. I am going to get both, it will be a few weeks though as I'm a bit low on funds. I'll keep you posted though.

[Tiki]

Originally Posted by Ronin_

Hi there bro - I have spoke to a few people now who say it is very good, and also a drug called Sodium Hydrlonate which is meant to be excellent. I am going to get both, it will be a few weeks though as I'm a bit low on funds. I'll keep you posted though.

Definitely keep us posted, bro. Good info here.

[einstein1905]

Originally Posted by Ronin_

Hi there bro - I have spoke to a few people now who say it is very good, and also a drug called Sodium Hydrlonate which is meant to be excellent. I am going to get both, it will be a few weeks though as I'm a bit low on funds. I'll keep you posted though.

I assume you meant sodium hyaluronate. The only stuff I'd use would be the prescription stuff like hyalgen, where you inject IA. I wouldn't even consider the oral stuff. The Adequan is pretty cheap. I think I'll give that a shot first. Do you know where you can get Hyalgen w/o a script? NOT a source post...just yes or no would be fine.

[Ronin_]

Yeh bro I can get the Hyalgen, it's $40 not sure on bottle size at mo.

[morepain]

Originally Posted by Ronin_

Yeh bro I can get the Hyalgen, it's $40 not sure on bottle size at mo.

there was an extensive thread on this subject on bolex, seems like great stuff especially for us older guys, if anyone finds a good source please PM me

[butthead]

Originally Posted by Ronin_

Yeh bro I can get the Hyalgen, it's $40 not sure on bottle size at mo.

check out www.anabolicboard.com they have alot of good info on this Adequan product

[patches prescott]

i'm very interested in the adequan

is there any problem with doing it while on a cycle?

also - this may sound ignorant, but what the hell is an intra-articular injection?

[einstein1905]

Originally Posted by patches prescott

i'm very interested in the adequan

is there any problem with doing it while on a cycle?

also - this may sound ignorant, but what the hell is an intra-articular injection?

I just ordered some Adequan last night. it seems like the script is not necessary when ordering from this site.
Intra-articular injection is into the joint capsule itself.
Actually I did a little more reading up on it, and the 30-40% binding by albumin in serum is the same for both canines and humans, so IM at the recommended canine doses should be fine. I should have it by the end of the week. I'll let you all know how it goes.

[Ronin_]

Any sites that sell it - can you guys keep it to PM we don't want it getting tighter for us

[einstein1905]

Originally Posted by Ronin_

Any sites that sell it - can you guys keep it to PM we don't want it getting tighter for us

Clean out your PM box, Ronin.

[Ronin_]

Originally Posted by einstein1905

Clean out your PM box, Ronin.

Ok give me a minute bro

[chuck89gt]

Ok I just placed an order with an online website that was SUPOSSED to be a no hassle site but no they are saying they wont ship till they get prescription info. I need to get my hands on Adequan like right now. Can some one help me please!